Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | LDHA | P00338 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.34 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.34 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.34 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.34 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11220224 | 0.83 | MAPT (0.35) | SIGMAR1LDHATRPM8GRIN1GRIN2A | |
| SCHEMBL3433240 | 0.78 | SIGMAR1 (0.48) | SIGMAR1DRD2HTR2ATRPM8MAOB | |
| SCHEMBL10744650 | 0.73 | SIGMAR1 (0.49) | SIGMAR1DRD2HTR2ATRPM8KDM1A | |
| SCHEMBL30211327 | 0.73 | SIGMAR1 (0.49) | SIGMAR1DRD2HTR2ATRPM8KDM1A | |
| SCHEMBL3926924 | 0.69 | SIGMAR1 (0.47) | SIGMAR1DRD2HTR2ATRPM8KDM1A | |
| SCHEMBL3113866 | 0.66 | SIGMAR1 (0.45) | SIGMAR1DRD2HTR2ATRPM8KDM1A | |
| SCHEMBL6467973 | 0.66 | SIGMAR1 (0.45) | SIGMAR1DRD2HTR2ATRPM8KDM1A | |
| SCHEMBL3560241 | 0.66 | SIGMAR1 (0.57) | SIGMAR1DRD2HTR2ATRPM8MAOB | |
| SCHEMBL462820 | 0.66 | SIGMAR1 (0.45) | SIGMAR1DRD2HTR2ATRPM8KDM1A | |
| SCHEMBL29392702 | 0.66 | SIGMAR1 (0.45) | SIGMAR1DRD2HTR2ATRPM8KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1200074-A2 | USE OF DIPHENYLIODONIUM FOR THE ACTIVATION AND PROTECTION OF CYTOTOXIC LYMPHOCYTES | Maxim Pharmaceuticals, Inc. (US) | 2002-05-02 | — | — | EP | claimed |
| WO-2001006756-A2 | USE OF DIPHENYLIODONIUM FOR THE ACTIVATION AND PROTECTION OF CYTOTOXIC LYMPHOCYTES | MAXIM PHARMACEUTICALS, INC. (US) | 2001-01-25 | — | — | WO | claimed |
| EP-0025598-A1 | The use of 2-phenyltetralin derivatives, or heterocyclic analogues, in medicine and pharmaceutical compositions containing them | THE WELLCOME FOUNDATION LIMITED (GB) | 1981-03-25 | — | — | EP | claimed |
| US-11564967-B1 | Oral compositions containing extracts of a betel leaf and related methods | Huynh, Tran Ky (VN) | 2023-01-31 | — | — | US | disclosed |
| US-20170319470-A1 | METHODS OF MANUFACTURING VISCOUS LIQUID PHARMACEUTICAL FORMULATIONS | INTARCIA THERAPEUTICS, INC. | 2017-11-09 | — | — | US | disclosed |
| US-9724293-B2 | Methods of manufacturing viscous liquid pharmaceutical formulations | INTARCIA THERAPEUTICS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-8398967-B2 | Particle formulations for use in pharmaceutical compositions | INTARCIA THERAPEUTICS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20130052237-A1 | Methods of Manufacturing Viscous Liquid Pharmaceutical Formulations | INTARCIA THERAPEUTICS, INC. (US) | 2013-02-28 | — | — | US | disclosed |
| US-8257691-B2 | Composition and dosage form comprising a particle formulation and suspending vehicle | INTARCIA THERAPEUTICS, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-20110208168-A1 | PARTICLE FORMULATIONS FOR USE IN PHARMACEUTICAL COMPOSITIONS | INTARCIA THERAPEUTICS, INC. | 2011-08-25 | — | — | US | disclosed |
| US-20110195097-A1 | COMPOSITION AND DOSAGE FORM COMPRISING A PARTICLE FORMULATION AND SUSPENDING VEHICLE | INTARCIA THERAPEUTICS, INC. | 2011-08-11 | — | — | US | disclosed |
| WO-1998022114-A1 | A METHOD FOR PROMOTING TISSUE REPAIR | DUMEX-ALPHARMA A/S (DK) | 1998-05-28 | — | — | WO | disclosed |
| US-5651991-A | FATTY EMULSION OF NON-LIPOSOME PARTICLES CONTAINING DRUG IN CORE, AND HAVING LIPID SURFACE LAYER | NIPPON SHINYAKU CO. LTD. (JP) | 1997-07-29 | — | — | US | disclosed |
| EP-0315079-B1 | Drug carriers | NIPPON SHINYAKU CO LTD (JP) | 1995-03-01 | — | — | EP | disclosed |
| US-5286748-A | General method of shortening the duration of common colds by application of medicaments to tissues of oral cavity | EBY III GEORGE A (US) | 1994-02-15 | — | — | US | disclosed |
| US-4956351-A | INCLUSION COMPLEXESOFVIRICIDES; RHINITIS; SUSTAINED RELEASE; NONIRRITATING TO MUCOUS MEMBRANE | JANSSEN PHARMACEUTICA N.V. FRAME-543 (BE) | 1990-09-11 | — | — | US | disclosed |
| EP-0315079-A1 | Drug carriers | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1989-05-10 | — | — | EP | disclosed |
| EP-0300526-A2 | Antiviral pharmaceutical compositions containing cyclodextrins | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-01-25 | — | — | EP | disclosed |
| EP-0207116-A1 | IMPROVEMENTS RELATING TO THE TREATMENT CONTROL AND PREVENTION OF RHINOVIRUS INFECTIONS | TYRRELL, David Arthur John (GB) | 1987-01-07 | — | — | EP | disclosed |
| WO-1986003412-A1 | IMPROVEMENTS RELATING TO THE TREATMENT CONTROL AND PREVENTION OF RHINOVIRUS INFECTIONS | TYRRELL DAVID ARTHUR JOHN | 1986-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195097-A1 | COMPOSITION AND DOSAGE FORM COMPRISING A PARTICLE FORMULATION AND SUSPENDING VEHICLE | ABCB11, SLC47A1, AQP1 | SIGMAR1 307/4885LDHA 3096/4885DRD2 3031/4885 |
| US-20170319470-A1 | METHODS OF MANUFACTURING VISCOUS LIQUID PHARMACEUTICAL FORMULATIONS | AQP1, AQP3, ABCB11 | SIGMAR1 1098/4885LDHA 1804/4885DRD2 3261/4885 |
| US-20110208168-A1 | PARTICLE FORMULATIONS FOR USE IN PHARMACEUTICAL COMPOSITIONS | AQP1, AQP3, ABCB11 | SIGMAR1 381/4885LDHA 2593/4885DRD2 3010/4885 |
| US-20130052237-A1 | Methods of Manufacturing Viscous Liquid Pharmaceutical Formulations | AQP1, AQP3, ABCB11 | SIGMAR1 1098/4885LDHA 1804/4885DRD2 3261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.